35
Participants
Start Date
May 6, 2016
Primary Completion Date
December 31, 2019
Study Completion Date
June 30, 2020
ibudilast
Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
Ibudilast
Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
South Shore Neurologic Associates, P.C., Patchogue
Massachusetts General Hospital, Boston
Lead Sponsor
Massachusetts General Hospital
OTHER
South Shore Neurologic Associates
INDUSTRY
MediciNova
INDUSTRY